Company InnoCan Pharma Corporation

INNO

CA45783P1027

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Other Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 09:30:00 2023-12-04 am EST			5-day change	1st Jan Change
0.32 ^CAD	0.00%		-5.88%	+48.84%

Nov. 29	InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
Nov. 29	InnoCan Pharma Brief: Says "Surge" in revenue Primarily attributable to "Robust" sales performance of Subsidiary, B.I. Sky Global Ltd.	MT

Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.

CAD in Million	2021	Weight	2022	Weight	Delta
Cannabidiol-integrated Pharmaceuticals 100.0 %	0	100.0 %	3	100.0 %	+1,255.72%

CAD in Million	2021	Weight	2022	Weight	Delta
United States 94.5 %	0	17.3 %	3	94.5 %	+7,281.67%
United Kingdom 3.2 %	-	-	0	3.2 %	-
Rest of the World 2.3 %	0	20.9 %	0	2.3 %	+49.43%

Managers	Title	Age	Since
Nir Avram FOU	Founder	70	-
Iris Or Gabi Bincovich FOU	Founder	-	2018
Yoram Drucker FOU	Founder	58	2018
Nelson Halpern DFI	Director of Finance/CFO	-	-
Roni Kamhi COO	Chief Operating Officer	-	2022
Eyal Flom BRD	Director/Board Member	58	2019

Members of the board	Title	Age	Since
Yoram Drucker FOU	Founder	58	2018
Peter Bloch BRD	Director/Board Member	63	2020
Ron Abraham Mayron CHM	Chairman	59	2014
Iris Or Gabi Bincovich FOU	Founder	-	2018
Eyal Flom BRD	Director/Board Member	58	2019
Ralph Bossino BRD	Director/Board Member	-	2019
Joshua Aaron Lintern BRD	Director/Board Member	36	2019

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	252,044,052	210,103,934 ( 83.36 %)	0	83.36 %

Name	Equities	%	Valuation
Solsken Ltd. 18.95 %	49,726,311	18.95 %	11 M $
Ron Abraham Mayron 1.966 %	5,160,000	1.966 %	1 M $
Iris Or Gabi Bincovich 1.090 %	2,859,750	1.090 %	634 865 $
Eyal Flom 0.7001 %	1,837,500	0.7001 %	407 925 $
PP-Asset Management GmbH 0.2012 %	528,000	0.2012 %	117 216 $
Nelson Halpern 0.0762 %	200,000	0.0762 %	44 400 $
Peter Bloch 0.000000 %	0	0.000000 %	- $
Ralph Bossino 0.000000 %	0	0.000000 %	- $
Joshua Aaron Lintern 0.000000 %	0	0.000000 %	- $
Roni Kamhi 0.000000 %	0	0.000000 %	- $

InnoCan Pharma Corp.

525-8th Avenue SW Suite 2400

T2P 1G1, Calgary

+403-777-1519

http://www.innocanpharma.com

address InnoCan Pharma Corporation(INNO)

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
INNOCAN PHARMA CORPORATION	+48.84%	64 M $
ELI LILLY AND COMPANY	+59.64%	525 B $
JOHNSON & JOHNSON	-10.34%	381 B $
MERCK & CO., INC.	-6.75%	262 B $
ABBVIE INC.	-11.26%	253 B $
ROCHE HOLDING AG	-16.04%	221 B $
NOVARTIS AG	+2.58%	202 B $
ASTRAZENECA PLC	-9.00%	200 B $
PFIZER, INC.	-43.58%	163 B $
AMGEN INC.	+3.74%	146 B $